Table 1. List of compounds used in this study.
| Drugs* | Target | IC50** |
|---|---|---|
| Taxol | Microtubule Stabilizing | 10 nM |
| Nocadazole | Microtubule Destabilizing | 5 μM |
| SAHA | Histone Deacetylase | 2 μM |
| Romidepsin | Histone Deacetylase | 2 nM |
| Olaparib | Poly ADP Ribose Polymerase | 10 μM |
| LMP400 | Topoisomerase I | 50 nM |
| Gemcitabine | Ribonucleotide Reductase | 50 nM |
| PF-2771 | CENP-E | 10 μM |
| GSK923295*** | CENP-E | 10 μM |
| Zoledronic acid | CENP-F | 10 μM |
| siRNA target | Sense sequence as ordered**** |
siRNA per well (6-well plate) |
| SKA3 | 5′-AGACAAACAUGAACAUUAAUU-3′ | 25 pmol |
| CENP-E | 5′-AACACGGAUGCUGGUGACCUC-3′ | 25 pmol |
| MIS18β | 5′-AGGCAGUACUUACAACCUUUU-3′ | 25 pmol |
| ON-TAGET plus, Non-targeting pool | 5′-UGGUUUACAUGUCGACUAA-3′ 5′-UGGUUUACAUGUUGUGUGA-3′ 5′-UGGUUUACAUGUUUUCUGA-3′ 5′-UGGUUUACAUGUUUUCCUA-3′ |
25 pmol |
*
All drugs, except RF-1771, GSK92395 and zoledronic acid, were described in our previous publications [15, 25]. GSK92395 was purchased from Selleckchem (Catalog no. S7090). PF-1771 was kindly provided by Dr. B.W. Murray (Pfizer Worldwide Research and Development, La Jolla Laboratories, San Diego). Zoledronic acid was purchased from Novartis Pharma AG (Stein, Switzerland).
**
The cells were treated overnight.
***
For HT1080 cells containing EGFP-HAC, IC50 for GSK923295 was 2 μM. For HT1080 cells containing mCherry-shRNA-HAC, IC50 was 10 μM.
****
The two underlined uracil (UU) were added by Dharmacon as part of siRNA construction.